Cargando…

Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma

Uveal melanoma differs from cutaneous melanoma with respect to aetiology, metastatic behaviour and immune biology. The notion that loss of classical MHC class I molecules in uveal melanoma lesions is associated with an improved prognosis suggests that NK cells act as the predominant cells responsibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Vetter, C S, Lieb, W, Bröcker, E-B, Becker, J C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409941/
https://www.ncbi.nlm.nih.gov/pubmed/15381927
http://dx.doi.org/10.1038/sj.bjc.6602123
_version_ 1782155905528233984
author Vetter, C S
Lieb, W
Bröcker, E-B
Becker, J C
author_facet Vetter, C S
Lieb, W
Bröcker, E-B
Becker, J C
author_sort Vetter, C S
collection PubMed
description Uveal melanoma differs from cutaneous melanoma with respect to aetiology, metastatic behaviour and immune biology. The notion that loss of classical MHC class I molecules in uveal melanoma lesions is associated with an improved prognosis suggests that NK cells act as the predominant cells responsible for immune surveillance of this tumour. Consequently, immune escape mechanisms of uveal melanoma should impair the innate immunity. To this end, expression of the ligand for the NK receptor NKG2D, that is, MIC-A/B was expressed by 50% of primary tumours, but none of the metastatic lesions. MIC(+) tumours were characterised by a NKG2D(+) infiltrate, which was absent in MIC(−) lesions subsequent to chemoimmune therapy. Strikingly, MIC-A/B expression in metastatic lesions was observed subsequent to chemotherapy with fotemustine in one case. In summary, MIC/NKG2D interactions seem to be involved in the immune surveillance of primary uveal melanomas, whereas for metastatic tumours this ligand/receptor system seems not to be relevant, thus, suggesting an immune selection of MIC negative tumour cells.
format Text
id pubmed-2409941
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24099412009-09-10 Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma Vetter, C S Lieb, W Bröcker, E-B Becker, J C Br J Cancer Molecular and Cellular Pathology Uveal melanoma differs from cutaneous melanoma with respect to aetiology, metastatic behaviour and immune biology. The notion that loss of classical MHC class I molecules in uveal melanoma lesions is associated with an improved prognosis suggests that NK cells act as the predominant cells responsible for immune surveillance of this tumour. Consequently, immune escape mechanisms of uveal melanoma should impair the innate immunity. To this end, expression of the ligand for the NK receptor NKG2D, that is, MIC-A/B was expressed by 50% of primary tumours, but none of the metastatic lesions. MIC(+) tumours were characterised by a NKG2D(+) infiltrate, which was absent in MIC(−) lesions subsequent to chemoimmune therapy. Strikingly, MIC-A/B expression in metastatic lesions was observed subsequent to chemotherapy with fotemustine in one case. In summary, MIC/NKG2D interactions seem to be involved in the immune surveillance of primary uveal melanomas, whereas for metastatic tumours this ligand/receptor system seems not to be relevant, thus, suggesting an immune selection of MIC negative tumour cells. Nature Publishing Group 2004-10-18 2004-09-21 /pmc/articles/PMC2409941/ /pubmed/15381927 http://dx.doi.org/10.1038/sj.bjc.6602123 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Vetter, C S
Lieb, W
Bröcker, E-B
Becker, J C
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
title Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
title_full Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
title_fullStr Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
title_full_unstemmed Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
title_short Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
title_sort loss of nonclassical mhc molecules mic-a/b expression during progression of uveal melanoma
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409941/
https://www.ncbi.nlm.nih.gov/pubmed/15381927
http://dx.doi.org/10.1038/sj.bjc.6602123
work_keys_str_mv AT vettercs lossofnonclassicalmhcmoleculesmicabexpressionduringprogressionofuvealmelanoma
AT liebw lossofnonclassicalmhcmoleculesmicabexpressionduringprogressionofuvealmelanoma
AT brockereb lossofnonclassicalmhcmoleculesmicabexpressionduringprogressionofuvealmelanoma
AT beckerjc lossofnonclassicalmhcmoleculesmicabexpressionduringprogressionofuvealmelanoma